A path forward.
Our INTERACT meeting with the FDA is complete. ETB-001 is on the biologic pathway, toward a BLA.
September 2026
Welcome to the first edition of the Etienna Bio newsletter. We're excited to bring you along as we build the future of regenerative aesthetics. Here's an update on our progress and where we're headed.
🧬 The INTERACT meeting is complete — providing early feedback from FDA
On August 28, Etienna Bio completed its INTERACT meeting with the FDA's Center for Biologics Evaluation and Research (CBER) for ETB-001, our lead regenerative aesthetics program.
ETB-001 is an autologous injectable cell product: a patient's own adipose-derived cells combined with our proprietary extracellular matrix scaffold to restore living soft tissue, beginning with the back of the hand. CBER gave us feedback on the nonclinical, manufacturing, and clinical work required to reach pre-IND. That feedback is now shaping our development plan.
⚖️ The BLA pathway — why it matters
Fat transfer is one of the most established procedures in aesthetics, but it remains for the most part a surgical one: harvest, processing, and reinjection, with results that vary with technique and graft survival. ETB-001 is designed to move that market toward a standardized injectable. Because it is a culture-expanded cell product, it is regulated as a biologic and being developed toward a Biologics License Application, the same standard the FDA applies to cell and gene therapies.
A product approved on that pathway is eligible for 12 years of regulatory exclusivity, and ETB-001 is further supported by a licensed patent estate. The bar is higher than for device-cleared products; so is the durability of the position if we clear it.
🔬 The 26-week primate study has concluded — no adverse findings
Our 26-week non-human primate safety study has concluded, with results slated for publication in Nature Communications Materialsby year's end. A preview: the data revealed no adverse findings, further reinforcing the safety profile of our platform. We'll include a link to the full report in our next newsletter.
👥 Our team — the co-founders
Janet DeLeon
President & CEO
Robert Lewis
Chairman
Missy Clifton, MD
Chief Medical Officer
Tim Dugan
Chief Clinical Officer
📍 Where to find us — upcoming events
If you want to meet at any of these, get in touch.
My thanks to our scientific founders at UMass Chan Medical School, the Etienna team, and our investors.
With foundational science licensed from UMass Chan and guidance from world-class advisors in adipose biology, Etienna Bio is closer than ever to bringing living, autologous tissue solutions to patients. We can't get there without financial support. Consider partnering with us to help fund the next stage of this work.
Thank you for being early,
Janet DeLeon
President & CEO, Etienna Bio
Forward-Looking Statements
This newsletter contains forward-looking statements, including statements regarding the development of ETB-001, the company's regulatory strategy and anticipated interactions with FDA, planned nonclinical and clinical studies, and the potential benefits of ETB-001. These statements are based on current expectations and are subject to risks and uncertainties, including the outcome of nonclinical studies, the timing and results of regulatory submissions, the company's ability to obtain financing, and other risks inherent in the development of biologic products. Actual results may differ materially. FDA feedback provided through the INTERACT program is preliminary and non-binding. ETB-001 is an investigational product and has not been approved by FDA or any other regulatory authority for any use. Etienna Bio undertakes no obligation to update these statements.